Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Abroad (travel likely)Recruiting

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Peng MD, Wang) · peng_wang@fudan.edu.cn · +86021-64041990

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases · Hepatocellular Carcinoma · Immunotherapy

Abroad (travel likely)Recruiting

Guanzhou, China